ImmunoPrecise Antibodies Sells Netherlands Operations to AVS Bio for $12M to Fuel AI-Driven Biologics Discovery

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has completed the sale of its Netherlands-based subsidiary, ImmunoPrecise Antibodies (Europe) B.V., to AVS Bio for an enterprise value of $12 million USD. The transaction, conducted through a competitive, arm’s-length process, delivered $11.7 million in net proceeds on a cash-free, debt-free basis. AVS Bio, a portfolio company of Arlington Capital Partners, is a global provider of critical bioprocessing inputs and services for the biologics and vaccine industries. The divestiture marks a key step in IPA’s strategic realignment, allowing the company to streamline operations, strengthen its financial position, and focus resources on its core growth initiatives—particularly its AI-native Software as a Service (SaaS) platform. The proceeds will be reinvested into scientific platforms, data-driven discovery technologies, and the expansion of key strategic programs. Dr. Jennifer Bath, President and CEO of ImmunoPrecise Antibodies Ltd., stated, “This transaction delivers strong value to IPA and our investors. It reflects our disciplined strategy to concentrate on our AI-based SaaS platform, where we’re combining deep scientific expertise with advanced technologies to accelerate biologics discovery. We’re proud of the business we’ve built in the Netherlands and confident it will continue to thrive under AVS Bio’s ownership.” IPA’s core capabilities span biologics discovery, engineering, and characterization, powered by its proprietary LENSai™ platform. LENSai leverages HYFT® multi-omics technology to unify and interpret complex biological data across different modalities, enabling more integrated insights and faster, smarter decision-making throughout the drug development lifecycle. A 12-month Transition Services Agreement (TSA) will ensure continuity in key functions during the handover. Beyond the TSA, IPA has no material ongoing relationship with AVS Bio or its affiliates. Edgemont Partners served as the exclusive financial advisor to ImmunoPrecise Antibodies Ltd. in the transaction. The sale underscores IPA’s shift toward becoming a leader in AI-driven biologics discovery, aligning with broader industry trends where data integration and machine learning are transforming R&D efficiency. As competition intensifies in the biotech and SaaS spaces, IPA aims to scale its LENSai platform and deepen its impact across global drug development pipelines. Forward-looking statements in this release, including expectations around platform scalability, market adoption, and strategic reinvestment, are subject to risks and uncertainties. Actual results may differ due to factors such as execution challenges, technological innovation pace, competitive dynamics, customer adoption, and regulatory or economic changes. Additional details are available in IPA’s Annual Report on Form 20-F for the fiscal year ended April 30, 2025, accessible via SEDAR+ and EDGAR.